Inovum Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Inovum HCT is used to manage hypertension by acting on the renin‑angiotensin system, calcium channels, and renal fluid excretion.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Secondary hypertension: assists in controlling blood pressure when caused by identifiable underlying conditions.
• Hypertension with renal involvement: provides effective pressure reduction while promoting diuresis.
• Isolated systolic hypertension: improves arterial compliance and lowers systolic pressure.
• Hypertension in elderly patients: offers once‑daily dosing convenience and balanced blood pressure control.

• Olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth muscle, causing arterial dilation. Hydrochlorothiazide acts on the distal convoluted tubule to increase sodium and water excretion, lowering plasma volume. Together, these mechanisms provide complementary control of both vascular tone and fluid balance, resulting in sustained blood pressure reduction.

Inovum HCT may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness: light‑headed feeling, often occurring when standing quickly.
• Headache: mild to moderate pain in the head region.
• Peripheral edema: swelling of the ankles or lower legs.
• Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Electrolyte disturbances: abnormal sodium or potassium levels that may affect heart rhythm.

When prescribing Inovum HCT, clinicians should consider several precautionary measures to ensure safe use.

• Blood pressure monitoring: check BP regularly to assess therapeutic response.
• Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
• Electrolyte surveillance: monitor sodium and potassium levels, especially in patients on diuretics.
• Concomitant drug review: avoid use with potassium‑sparing diuretics or strong CYP3A4 inhibitors.
• Pregnancy and lactation: use only if benefits outweigh potential risks, after professional evaluation.
• Store at room temperature: keep tablets in original container, protect from moisture and light.

Inovum HCT can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.
• NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine concentrations.
• Other antihypertensives (e.g., beta‑blockers): additive blood pressure lowering, risk of hypotension.
• Antidiabetic agents: diuretic component may affect glucose control.